This study evaluates the T3 implant system for the preservation of alveolar crestal bone and the establishment of initial integration. The new surface-treated features of the implant may contribute to improved soft and hard tissue healing. The success rate of the T3 implant will be no different than that of the control implant, which possess similar geometry but different surface treatments.
This prospective, randomized-controlled study will enroll qualified patients with partial edentulism who will be treated with at least two dental implants. Implant sites will be randomly assigned to receive either a test (T3 implant) or control (Nanotite Certain Tapered implant) with an 80:20 (test:control) randomization ratio. All implants will be allowed to integrate without occlusal forces and final restorations will be cemented thereafter. Cumulative success rate and crestal bone regression of both treatment groups will be the primary and secondary study endpoints, respectively.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
40
T3 with DCD implant with Certain (internal) connection and platform-switch design
Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
Dr. Tommie VanDeVelde
Antwerp, Belgium
Dr. Dominique Caspar
Les Bains, France
Dr. Felix Hanssler
Göppingen, Germany
Dr. Nicholas Lewis
London, United Kingdom
Cumulative success rate
Implant mobility is assessed by clinical evaluations and correlation to initial placement stability- insertion torque profiles.
Time frame: 1 year
Crestal bone changes
Crestal bone regression (amount of bone loss) between the two treatment groups will be compared
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.